{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-22-000103","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.679600+00:00","generated_at":"2026-06-22T07:59:37.331593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics Q3 net loss narrows to $24.8M; receives $60M Gilead upfront; cash runway into mid-2024","bullets":["Q3 total revenue $41.7M (up from $15.7M YoY) including $30M Incyte milestone and $4.4M MARGENZA sales.","Net loss $24.8M ($0.40/share) vs $52.9M ($0.86/share) in Q3 2021; R&D spend $48.2M.","Cash $123.6M at Sep 30, plus $60M from Gilead in Oct; cash runway extended into mid-2024.","Gilead collaboration for MGD024 and up to two bispecific programs; potential $1.7B in milestones plus tiered royalties.","Teplizumab PDUFA date Nov 17, 2022; if approved, MacroGenics eligible for $60M milestone from Provention Bio."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-22-000103","json":"https://secwatch.observer/filing/0001125345-22-000103.json","markdown":"https://secwatch.observer/filing/0001125345-22-000103.md","text":"https://secwatch.observer/filing/0001125345-22-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/0001125345-22-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/mgnx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:59:37.331593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da61a7d7edf0aac54a174f8877154c2114ae8db6","claim":"MACROGENICS INC reported the quarter ended September 30, 2022 results: revenue $41.7 million.","evidence_excerpt":"Total revenue, consisting primarily of revenue from collaborative agreements, was $41.7 million for the quarter ended September 30, 2022, compared to total revenue of $15.7 million for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/0001125345-22-000103-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$41.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}